Health & Biotech
Growing Goliaths: NGS scientifically-backed products to unlock kids’ highest potential
Health & Biotech
Dr Boreham’s Crucible: A Pfizer takeover could make Resapp a genuine chestbeater
Health & Biotech
Fighting Back: 3 ASX cancer stocks giving hope in a leading cause of death
Health & Biotech
5 thematics to bring the Australian life sciences sector back in from the cold
Health & Biotech
Weed Week: US seed bank launches 4/20 day NFT collection and Washington has a cannabis tax holiday
Health & Biotech
Going big: Nutritional Growth Solutions executes Asia Pacific strategy with initial rollout of Kiwi-made products
Health & Biotech
Medlab Clinical shares up ~13% after UK trade deal for patented probiotic NRGBiotic
Health & Biotech
PharmAust confirms cash boost for Phase 1 trials, with ATO approval for federal R&D refund
Health & Biotech
Osteopore expands further into Europe after delivering maiden sale to Spain
Health & Biotech
ASX Health Stocks: EU approval set to open up Wellfully’s knee patch to European markets
Health & Biotech
Check Up: Biotechs are going through a rough patch, but recent ASX IPOs haven’t flopped too badly
Health & Biotech
Medlab just axed another Q3 and now the Aussie world beater’s ready to deploy its vast global network
Featured Health & Biotech Stocks
Health & Biotech
Healthcare stocks are as varied as the solutions they are working to solve. The sector covers biotech stocks developing breakthrough pharmaceutical drugs and vaccines to medtech companies launching the latest and greatest medical devices they hope will change the face of healthcare.
Even the ‘budding’ medical cannabis industry is in the mix as researchers explore new applications and treatments.
If you want to know what’s happening with emerging health stocks on the ASX, Stockhead has you covered, with daily stock news, expert insight and research. You can also recap broader industry trends and recent share price movements across the sector in our regular ‘Check Up’ feature.
Accurate, up-to-date news stories are important, especially in the health sector where progress is often slow and risk often high. That’s why we’re focused on helping small cap investors make sense of the medical jargon.